A Letter from Prodigy’s CEO to the DEA
Support of the DEA's proposed rescheduling of marijuana from Schedule I to Schedule III
Forward Note:
Moving cannabis to Schedule III would mark a significant advancement in U.S. cannabis reform—a change supported by 88% of Americans according to Pew Research. The reclassification may influence research and development planning, while FDA approval, DEA controls, and product-specific requirements remain distinct considerations for any cannabis-derived drug product. The advent of federal regulation is set to substantially enhance both product quality and consumer safety, potentially redefining the medical marijuana industry, which has until now been monitored only by local health departments that lack the subject matter expertise and broad reach of the FDA.
The FDA’s regulatory acumen will play a crucial role in fulfilling the need for standardization and stringent consumer safety standards that has long been overlooked. From its inception, Prodigy has only designed and manufactured cannabis and hemp extraction equipment that not only complies with but exceeds pharmaceutical and cGMP standards, thereby seamlessly aligning the FDA’s stringent regulations with our dedication to consumer safety.
Public comments to the DEA on rescheduling cannabis from Schedule I to Schedule III ended a day ago with a remarkable 42,925 submissions from interested parties. PRODIGY chimed in with strong support of the measure due to the massive opportunities it will create for forward-looking extraction labs that step up to pharmaceutical FDA cGMP standards and obtain DEA registration. Teams pursuing pharmaceutical projects should evaluate the applicable FDA, DEA, state, and international requirements for their specific products and activities.
If your lab is ready to go pharma GMP, we’ll get you there in record speed!
Marc Beginin – Founder/CEO, Prodigy Processing Solutions
Letter to DEA:
The communication as filed with Regulations.Gov may be found here.
The rescheduling of cannabis to Schedule III represents the most significant regulatory shift in decades. Operators who prepare now — with pharmaceutical-grade equipment and GMP protocols — will be first in line when the new framework takes effect.
Prepare for the Regulatory Shift
Prodigy is building the equipment infrastructure for cannabis's pharmaceutical future. Our systems are engineered for customers evaluating equipment, documentation, and quality considerations as regulatory requirements continue to evolve.